Huang Wenmian, Liu Tao, Feng Guodong, Wang Xin
Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. *Corresponding author, E-mail:
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2020 Nov;36(11):1044-1048.
The research and development of the coronavirus disease 2019 (COVID-19) vaccine is being carried out globally. Although vaccine research and development technology has made great progress, the possibility of obtaining a safe and effective vaccine that can control the global epidemic in a short period of time is still low due to the antibody-dependent enhancement effect (ADE) of the vaccine and the mutation of the virus. In the absence of specific treatment for COVID-19, finding other alternative protection schemes has become another treatment idea. Epidemiological studies have found that, in this COVID-19 epidemic, countries with long-term Bacillus Calmette-Guerin (BCG) vaccination policies have relatively less cases and lower mortality rates than countries without relevant policies. This phenomenon may be related to the "training immunity" effect of BCG. In order to further clarify the preventive and protective effects of BCG vaccine on SARS-CoV-2 infection, a number of clinical trials are underway.
2019冠状病毒病(COVID-19)疫苗的研发正在全球范围内进行。尽管疫苗研发技术取得了巨大进展,但由于疫苗的抗体依赖性增强效应(ADE)和病毒变异,在短时间内获得一种能够控制全球疫情的安全有效疫苗的可能性仍然很低。在缺乏针对COVID-19的特异性治疗方法的情况下,寻找其他替代保护方案已成为另一种治疗思路。流行病学研究发现,在这次COVID-19疫情中,长期实施卡介苗(BCG)接种政策的国家比没有相关政策的国家病例相对较少,死亡率也较低。这种现象可能与卡介苗的“训练免疫”效应有关。为了进一步阐明卡介苗对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的预防和保护作用,多项临床试验正在进行中。